Compare stocks

OWLT vs TLSI

Owlet, Inc. and TriSalus Life Sciences, Inc. Common Stock

Compare the businesses

Owlet, Inc.

Owlet, Inc. provides digital parenting solutions in the United States, the United Kingdom, and internationally. The company offers a digital parenting platform that provides real-time data and insights to parents. It also provides sock monitors, including Dream Sock, a wearable infant health monitor equipped with pulse oximetry technology that tracks vital signs, such as pulse rate, activity, oxygen level, and sleep patterns; BabySat, which is intended for infants with conditions, including respiratory syncytial virus, pneumonia, bronchitis, croup, and other diagnoses; and Owlet Smart Sock, which provides real-time heart rate and oxygen readings in the Owlet Care App. In addition, the company offers Owlet Cam, an audio and video monitor that has 1080p HD video, motion and cry detection, 4x zoom, and two-way audio; Dream Duo, a baby monitoring solution that combines Dream Sock or Owlet Smart Sock with Owlet Cam; Owlet360, a subscription service that provides personalized understanding of the babies' development, health, and sleep trends; and accessories, such as fabric accessory socks, the Owlet Dream Sleeper with Swaddle, and the Owlet Sock Travel Case. Owlet, Inc. was founded in 2012 and is headquartered in Lehi, Utah.

Open OWLT dashboard ↗

TriSalus Life Sciences, Inc. Common Stock

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Open TLSI dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

Sign in →

New to NexusTrade? Create a free account.

Choose another comparison ↗